Represented Endologix, Inc. (NasdaqGS: ELGX) in its merger with TriVascular Technologies, Inc. (NasdaqGS: TRIV).
The combined company expects to be a global leader in the development, manufacture and sale of innovative therapies for the treatment of abdominal aortic aneurysms. The combined company’s product portfolio currently includes the TriVascular Ovation, Endologix AFX and Endologix Nellix systems for endovascular aneurysm repair and endovascular aneurysm sealing. The combined company expects to introduce new products in the coming years, with a forecasted compound annual growth rate of 20% over the next five years.
The deal team representing Endologix was led by Larry Cohn.